Everest Medicines Secures Exclusive License for Sumecigrel in Asia-Pacific, Expanding Its Cardiovascular Product Portfolio
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Everest Medicines Secures Exclusive License for Sumecigrel in Asia-Pacific, Expanding Its Cardiovascular Product Portfolio
HONG KONG, Jun 9, 2026 - (ACN Newswire) - Everest Medicines today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. ("Vcare"), for the development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across the Asia-Pacific region, including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR, and Taiwan region, China. Pursuant to the agreement, Ever…
Everest Medicines Secures Exclusive License for Sumecigrel in Asia-Pacific, Expanding Its Cardiovascular Product Portfolio – EastMud
HONG KONG, Jun 9, 2026 – (ACN Newswire via SeaPRwire.com) – Everest Medicines today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. (“Vcare”), for the development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across the Asia-Pacific region, including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR, and Taiwan region, China. Pursuant to t…
Everest Medicines Secures Exclusive License for Sumecigrel in Asia-Pacific, Expanding Its Cardiovascular Product Portfolio – DIR HONGKONG
HONG KONG, Jun 9, 2026 – (ACN Newswire via SeaPRwire.com) – Everest Medicines today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. (“Vcare”), for the development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across the Asia-Pacific region, including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR, and Taiwan region, China. Pursuant to t…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
